Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis

about

Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis

Item

http://www.wikidata.org/entity/Q57114745

description

im Januar 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Farnesoid X receptor agonist I ...... f nonalcoholic steatohepatitis

@en

Farnesoid X receptor agonist I ...... f nonalcoholic steatohepatitis

@nl

type

Item

label

Farnesoid X receptor agonist I ...... f nonalcoholic steatohepatitis

@en

Farnesoid X receptor agonist I ...... f nonalcoholic steatohepatitis

@nl

prefLabel

Farnesoid X receptor agonist I ...... f nonalcoholic steatohepatitis

@en

Farnesoid X receptor agonist I ...... f nonalcoholic steatohepatitis

@nl

P1476

Farnesoid X receptor agonist I ...... f nonalcoholic steatohepatitis

@en

P2093

Wei Zhan

http://www.w3.org/2001/XMLSchema#string

Xin-Yu Liu

http://www.w3.org/2001/XMLSchema#string

Ying-Bin Hu

http://www.w3.org/2001/XMLSchema#string

P2860

Bile acid receptors and nonalcoholic fatty liver disease

Bile acids are nutrient signaling hormones

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.

Role of nuclear receptor SHP in metabolism and cancer.

Ageing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH

FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats.

TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading.

Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass.

Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis.

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.

P304

2213-2221

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DDDT.S170518

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30038487

http://www.w3.org/2001/XMLSchema#string

P921

Farmakologi

drug discovery

P932

6052932

http://www.w3.org/2001/XMLSchema#string